康龙化成收购美国Coventry原料药生产基地

圣剑之心

康龙化成收购美国罗德岛州Coventry的原料药生产基地，Coventry 生产基地配备了先进的生产设施，可提供从中试至吨级商业化规模的cGMP原料药生产服务，此举进一步增强了康龙化成在小分子CDMO服务能力。

5月24日，康龙化成（北京）新药技术股份有限公司（股票代码：300759.SZ / 3759.HK，以下简称“康龙化成”）宣布与美国Noramco签订资产购买协议，收购其位于美国罗德岛州Coventry的原料药生产基地（以下称：Coventry 生产基地），交易预计在满足惯例成交条件后完成。

Coventry 生产基地配备了先进的生产设施，可提供从中试至吨级商业化规模的cGMP原料药生产服务。多次通过包括美国食品及药物管理局（FDA）、欧洲药品管理局（EMA）在内的多家监管机构核查，拥有丰富的行业经验。

康龙化成致力于全流程、一体化平台的建设，此次收购将助力其在美国建立化学与生产服务能力。结合康龙化成在中国和英国的小分子CDMO服务能力，此举进一步增强了其在该领域的全球服务能力，有利于为客户提供定制化解决方案，更好地满足全球合作伙伴的战略需求。下载化学加APP，阅读更有效率。

康龙化成董事长兼首席执行官楼柏良博士表示：“欢迎Coventry 生产基地加入康龙化成。其优良的监管记录、丰富的商业化生产解决方案、经验丰富且稳定的团队，为我们在北美快速提高化学与生产能力提供了有利条件，丰富了我们的全球服务网络。此次收购是助力我们实现成为全球领先的药物研发及生产服务领军企业的又一重要举措。”

此次交易由O’Melveny和Ernst & Young分别担任康龙化成方法律顾问和财务顾问。

关于康龙化成

康龙化成新药技术股份有限公司（股票代码：300759.SZ / 3759.HK）是国际领先的生命科学研发服务企业。自2004年成立以来，康龙化成一直致力于其人才培养和设施建设，为包括小分子、大分子和细胞与基因治疗药物在内的多疗法药物研发打造了一个贯穿药物发现、临床前及临床开发全流程的研发生产服务体系。康龙化成在中国、美国、英国均开展运营，拥有15,000多名员工，向北美、欧洲、日本和中国的合作伙伴提供研发解决方案并与之保持良好的合作关系。

Pharmaron Acquires Commercial API Manufacturing Facility in the United States

Continues to strengthen its global chemistry and manufacturing capabilities and capacities

Beijing, China, May 24, 2022– Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has entered into a definitive Asset Purchase Agreement to acquire the Coventry API manufacturing site (the “Coventry Site”) in the United States from Noramco. The transaction is expected to close upon the satisfaction of customary closing conditions.

The Coventry Site in Rhode Island has an established history of cGMP API manufacturing from pilot kilogram to commercial metric ton scales. The state-of-the-art manufacturing facilities have been inspected and approved by the FDA, EMA and other regulatory authorities.

This acquisition expands Pharmaron's world-class chemistry and manufacturing global services into the US, which is an important component of its fully integrated platform. Together with the existing service capabilities and capacities in China and the UK, this site addition will further strengthen Pharmaron’s global end-to-end chemistry and manufacturing service offerings to provide customized solutions to meet our partners’ geographic and strategic needs.

Dr. Boliang Lou, Chairman and Chief Executive Officer of Pharmaron, commented, “We are delighted to have the Coventry Site join the Pharmaron Group. Its proven regulatory and commercial manufacturing track record, combined with the highly experienced and stable team, provides a unique opportunity to rapidly expand our chemistry and manufacturing services capabilities in North America and enrich our global network of services. This transaction is another important step in realizing our vision of becoming a leading global provider of integrated drug R&D and manufacturing services.”

O’Melveny acted as legal advisor and Ernst & Young acted as financial advisor to Pharmaron.

About Pharmaron

Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 15,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. www.pharmaron.com

来源：康龙化成

屏风

康龙化成板块扩大了

小邢

现在CRO都在海外增加生产基地，药明也是，美国、爱尔兰都增加了基地建设